Perspective Therapeutics, Inc.
corporate_fare Company Profile
Perspective Therapeutics, Inc. (NYSE:CATX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for CATX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for CATX spans 8-K.
Recent high-impact activity:
- Perspective Q3 2026: $202M Cash Into 2028, PSV359 Fast Track, Merck Collaboration
- Perspective Reports 75% Disease Control at 3.0 mCi in Heavily Pretreated Melanoma
- Perspective's VMT-α-NET Shows 75% 18-Month PFS in SSTR2+ GEP-NETs; End-of-Phase 2 Targeted 1Q 2027
Financial Snapshot
Short Interest & Short Volume
2.47 days to coverFINRA reported short interest of 8,974,834 shares in CATX as of the October 30, 2026 settlement, a 46.2% decrease from the prior period — about 2.5 days to cover at its recent average daily volume. On November 20, 2026, 57.0% of CATX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.